Clinical trials: Recurrent/Metastatic Endometrial Cancer, active
FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma
Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers
This phase Ib/II trial tests the safety, side effects, best dose, and effectiveness of the combination of ipatasertib with megestrol acetate to megestrol acetate alone in patients with endometrial cancer that has come back…
- Conditions
- FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, Metastatic Endometrial Endometrioid Adenocarcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma
- Trial name
- NCT05538897
- Testing
- Biospecimen Collection, Computed Tomography, Ipatasertib
- Where
- 152 sites in United States
- Volunteers
- 96 people
- Sponsor
- National Cancer Institute (NCI)
Endometrial Adenocarcinoma, Endometrial Cancer
QL1706-Based Therapy Post-PD-1/L1 Failure in Advanced Endometrial Cancer
This is a prospective, single-arm, multicenter Phase II study evaluating the efficacy and safety of QL1706 combined with chemotherapy in patients with advanced recurrent or metastatic endometrial cancer who progressed after prior…
- Trial name
- QLPPEC/GOG-003 (NCT06917092)
- Testing
- QL1706 combined with chemotherapy ± Bevacizumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Recurrent/Metastatic Endometrial Cancer
Adebrelimab Plus Carboplatin/Paclitaxel Followed by Adebelizumab with or Without Apatinib in the Treatment of Advanced Recurrent/Metastatic Endometrial Cancer (A-CAPE): a Multicenter, Randomized, Controlled, Open-Label Clinical Trial
This study takes investigator-assessed Progression-Free Survival (PFS) as the primary endpoint, with plans to enroll 140 patients with advanced recurrent/metastatic endometrial cancer in a 1:1 ratio, randomized into an…
- Trial name
- A-CAPE (NCT06771154)
- Testing
- Adebelimab Combined with Apatinib, Adebelimab
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Peking Union Medical College Hospital
Endometrial Adenocarcinoma, Metastatic Endometrial Cancer
Assessing Survival Outcomes With Checkpoint Inhibition ExteNded vs Discontinued in Endometrial Cancer
This is a pragmatic, non-inferiority randomized hybrid decentralized clinical trial. The goal of this study is to determine if one year of maintenance immunotherapy (anti-PD1 agent therapy; pembrolizumab or dostarlimab) is…
- Conditions
- Endometrial Adenocarcinoma, Metastatic Endometrial Cancer, Endometrial Cancer, Recurrent Endometrial Cancer
- Trial name
- ASCEND-EC-DCT (NCT07867002)
- Testing
- anti-PD1 agent therapy - 1 year, anti-PD1 agent therapy - 2 years
- Where
- 6 sites in United States
- Volunteers
- 140 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Endometrial Carcinoma, TP53 Mutation
Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer
This study is an open-label Phase II randomized controlled trial designed to evaluate the safety and efficacy of camrelizumab plus fluzoparib maintenance therapy in patients with recurrent or metastatic TP-53 mutated Endometrial…
- Conditions
- Endometrial Carcinoma, TP53 Mutation, Recurrent or Metastatic
- Trial name
- NCT06413992
- Testing
- Fluzoparib, Camrelizumab, paclitaxel (albumin bound)
- Where
- China
- Volunteers
- 117 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Endometrial Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
This phase II trial studies the effects of the combination of olaparib and durvalumab, cediranib and durvalumab, olaparib and capivasertib, and cediranib alone in treating patients with endometrial cancer that has come back…
- Conditions
- Endometrial Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma
- Trial name
- NCT03660826
- Testing
- Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy
- Where
- 761 sites in United States, Canada
- Volunteers
- 288 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Squamous Cell Carcinoma HNSCC, Non-Small Cell Lung Cancer NSCLC
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
This is a study to evaluate the safety and preliminary anti-tumor activity of STRO-004 in adults with metastatic cancer. This study includes 3 parts: Part 1A is a dose escalation study of STRO-004 monotherapy in selected tumor…
- Conditions
- Head and Neck Squamous Cell Carcinoma HNSCC, Non-Small Cell Lung Cancer NSCLC, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT07227168
- Testing
- STRO-004, Pembrolizumab
- Where
- 9 sites in United States
- Volunteers
- 200 people
- Sponsor
- Sutro Biopharma, Inc.
Gynecological Malignant Tumor, Solid Tumor
A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies
A phase Ib/II clinical study to evaluate the safety, tolerability, pharmacokinetics and efficacy of BL-B01D1 for injection in patients with multiple solid tumors, including recurrent or metastatic gynecological malignancies.
- Trial name
- NCT05803018
- Testing
- BL-B01D1
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Endometrial Cancer, Cervical Cancer
The Role of Micrometastasis and Isolated Tumor Cells (ITCs) in Endometrial and Cervical Cancer. A Multicenter Study.
The role of small-volume lymph node disease (ITC and micro metastases) among patients with endometrial or cervical cancer submitted to sentinel node (SLN) procedure is not clearly defined.
- Conditions
- Endometrial Cancer, Cervical Cancer, Sentinel Lymph Node, Micrometastasis
- Trial name
- ITCMicroUtCa (NCT04403867)
- Testing
- Sentinel lymph node (SLN) biosy +/- lymphadenectomy
- Where
- Italy
- Volunteers
- 500 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma
Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer
This randomized phase II trial studies how well cabozantinib s-malate and nivolumab work in treating patients with endometrial cancer that has come back (recurrent) or spread to other places in the body (advanced or metastatic).
- Conditions
- Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma, Recurrent Endometrial Carcinoma, Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
- Trial name
- NCT03367741
- Testing
- Biopsy Procedure, Biospecimen Collection, Cabozantinib S-malate
- Where
- 34 sites in United States, Canada
- Volunteers
- 82 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Endometrial Cancer
Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer
This research study is evaluating a drug called Avelumab alone and in combination with Talazoparib or Axitinib as a possible treatment for recurrent or metastatic endometrial cancer.
- Trial name
- NCT02912572
- Testing
- Avelumab, Talazoparib, Axitinib
- Where
- 4 sites in United States
- Volunteers
- 106 people
- Sponsor
- Dana-Farber Cancer Institute
Endometrial Cancer
Abemaciclib and Letrozole to Treat Endometrial Cancer
This is a phase II single arm trial to determine the percentage of patients without evidence of disease progression on abemaciclib and letrozole in advanced stage, persistent or recurrent endometrioid endometrial cancer at 6…
- Trial name
- NCT04393285
- Testing
- Abemaciclib, Letrozole
- Where
- 29 sites in United States
- Volunteers
- 53 people
- Sponsor
- Gynecologic Oncology Group
Metastatic Endometrial Carcinoma, Recurrent Endometrial Adenocarcinoma
VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer
This phase I trial studies the side effects and best dose of vesicular stomatitis virus-human interferon beta-sodium iodide symporter (VSV-hIFNbeta-NIS) with or without ruxolitinib phosphate in treating patients with stage IV…
- Conditions
- Metastatic Endometrial Carcinoma, Recurrent Endometrial Adenocarcinoma, Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma
- Trial name
- NCT03120624
- Testing
- Biopsy, Computed Tomography, Fluorine F 18 Tetrafluoroborate
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Mayo Clinic
Endometrial Cancer, Ovarian Cancer
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
HWK-007-101 is a multicenter, open-label, first-in-human (FIH) Phase 1 study evaluating HWK-007, a protein tyrosine kinase 7 (PTK7)-targeted antibody drug conjugate (ADC), in adult participants with advanced or metastatic solid…
- Conditions
- Endometrial Cancer, Ovarian Cancer, Ovarian Cancer Metastatic, Ovarian Cancer Metastatic Recurrent
- Trial name
- NCT07444814
- Testing
- HWK-007
- Where
- 12 sites in United States
- Volunteers
- 226 people
- Sponsor
- Whitehawk Therapeutics, Inc.
Ovarian Carcinosarcoma, Endometrial Carcinosarcoma
Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib
Carcinosarcomas (CS) (malignant mixed Müllerian tumors) are highly aggressive and rare tumors with a worldwide annual incidence between 0.5-3.3 cases/100.000 women. Gynecological CS, i.e.
- Trial name
- ROCSAN (NCT03651206)
- Testing
- Niraparib, Niraparib + TSR-042 (Dostarlimab), Chemotherapy Drugs
- Where
- 36 sites in France, Italy and 1 more
- Volunteers
- 138 people
- Sponsor
- ARCAGY/ GINECO GROUP
Head & Neck Squamous Cell Carcinoma, Non-Small Cell Lung Cancer
Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic
This study is a first-in-human (FIH) Phase 1 open-label, multicenter study including three parts: Part 1A is a dose escalation of STRO-006 monotherapy in selected tumor types reported to commonly express ITGB6.
- Conditions
- Head & Neck Squamous Cell Carcinoma, Non-Small Cell Lung Cancer, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT07807345
- Testing
- STRO-006, Pembrolizumab
- Where
- 6 sites in United States
- Volunteers
- 285 people
- Sponsor
- Sutro Biopharma, Inc.
Ovarian Cancer, Fallopian Tube Cancer
HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer
HS-20089 is an investigational antibody-drug conjugate (ADC) composed of a humanized IgG1 anti-B7-H4 monoclonal antibody conjugated to the topoisomerase I inhibitor payload via a protease-cleavable linker, with an average…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Endometrial Cancer
- Trial name
- NCT06014190
- Testing
- HS-20089
- Where
- 28 sites in China
- Volunteers
- 460 people
- Sponsor
- Hansoh BioMedical R&D Company
Recurrent or Metastatic Endometrial Cancer
QL1706 Combined with Chemotherapy in the Treatment of Recurrent or Metastatic Endometrial Cancer
the investigators planned to evaluate the efficacy and safety of QL1706 in combination with chemotherapy as first-line systemic therapy in approximately 26 patients with newly diagnosed recurrent or metastatic endometrial cancer…
- Trial name
- NCT06751277
- Testing
- QL1706 plus carboplatin plus paclitaxel for six to eight cycles at the investigator's discretion, followed by QL1706
- Where
- China
- Volunteers
- 26 people
- Sponsor
- xiang yang
Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma
Elacestrant With Everolimus for the Treatment of Recurrent Advanced or Metastatic ER-Positive Endometrial Cancer
This phase II trial tests how well elacestrant with everolimus works for the treatment of estrogen receptor (ER) positive endometrial cancer that has come back after a period of improvement (recurrent), that may have spread from…
- Conditions
- Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma, Recurrent Endometrial Carcinoma, Stage III Endometrial Cancer
- Trial name
- NCT07634601
- Testing
- Biospecimen Collection, Computed Tomography, Elacestrant
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Ovarian Neoplasms, Endometrial Cancer, Endometrial Neoplasm
BMX-001 + Paclitaxel in Adult Patients With Advanced, Recurrent, Metastatic Ovarian or Endometrial Cancer
This research project addresses the urgent need for novel therapeutic strategies to overcome chemotherapy resistance and mitigate chemotherapy-induced peripheral neuropathy (CIPN) in patients with recurrent ovarian and…
- Trial name
- NCT06620029
- Testing
- BMX-001, Paclitaxel (Taxol)
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- BioMimetix JV, LLC